Fosun Pharma Unit and Partners Form Shanghai Fuzhenkang Biotechnology
Shanghai Fuzhenkang Biotechnology Co. , Ltd. was recently established, with Zhang Haitao serving as its legal representative.
The company's business scope includes health consulting services (excluding diagnosis and treatment services), sales of wearable smart devices, sales of artificial intelligence hardware, and research and development of new materials technology.
Its equity structure shows that the company is jointly held by Fosun Diagnostics Technology (Shanghai) Co. , a wholly owned subsidiary of Fosun Pharma, and other shareholders.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is positive for Health Management & Diagnostics, with intensity 20/100 and 60% confidence over a medium term horizon.
Health Management & Diagnostics
- Direction
- positive
- Intensity
- 20
- Confidence
- 60%
- Horizon
- Medium term
Artificial Intelligence
- Direction
- positive
- Intensity
- 15
- Confidence
- 50%
- Horizon
- Medium term
Medical Equipment
- Direction
- positive
- Intensity
- 15
- Confidence
- 50%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.